TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
ERAS

Erasca Inc

Healthcare · Biotechnology

13.90$ -10.3% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ERAS
Line item 2019 2020 2021 2022 2023 2024 2025
– +124.9% +301.7% +2.7% -23.2% +27.1% -21.2%
– +134.7% +250.0% +5.8% -27.9% -3.7% -7.3%
– +121.0% +451.4% -21.2% -67.3% -27.2% +9.0%
– +135.7% +286.9% -5.1% -28.3% -4.5% -7.5%
– – – – – – +8.7%
– -6.1% +291.8% +55.5% – – –
– +245.5% -81.2% +129.6% -23.7% +0.5% -10.2%
– +397.5% +92.8% +84.6% -46.3% +20.0% -9.2%
– +20.8% -35.0% +357.9% +52.1% +132.7% -45.2%
– -36.4% +432.7% +392.8% -91.3% -76.6% +109.6%
– – – -9.8% -23.1% +33.7% -23.2%
– – – – – – –
– -80.5% +412.9% +2.5% +23.1% +94.6% +21.3%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?